<DOC>
	<DOCNO>NCT00910429</DOCNO>
	<brief_summary>Patients complete 16 week treatment CHEST-1 trial ( study number 11348 ) ask participate long term extension study BAY63-2521 . The aim long term study collect additional information evaluate safety tolerability BAY63-2521 . Patients treat open label medication individual optimal dose 0,5 mg - 2,5 mg tid .</brief_summary>
	<brief_title>BAY63-2521 - Long-term Extension Study Patients With Chronic Thromboembolic Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patients complete 16 week treatment double blind trial CHEST 1 Patients ongoing serious adverse event CHEST 1 assess related BAY632521 allow participate extension trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic thromboembolic Hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>soluble Guanylate Cyclase Stimulator</keyword>
	<keyword>sGC</keyword>
</DOC>